Cipla gets USFDA OAI status for Goa facility
Advertisement
Mumbai: Pharma major Cipla has announced that the company has received a communication from the US Food and Drug Administration (USFDA) that the classification of Company's Goa facility continues to be as Official Action Indicated ("OAI"). Official Action Indicated (OAI) means regulatory and/or administrative actions will be recommended.
"USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved. The Company has an ongoing de-risking plan in place for new product approvals," the company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.